Related Experiment Video
Updated: Sep 13, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Management of Anticoagulation in Antiphospholipid Syndrome and Systemic Lupus Erythematosus With Concurrent
Teresa Mota1, Rita Queirós Pereira1, Diana Leão1
1Immunohemotherapy Department, Unidade Local de Saúde de São João, Porto, PRT.
Abstract:
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by arterial, venous, or small-vessel thromboembolic events and/or pregnancy morbidity in the presence of antiphospholipid antibodies. APS can occur in the setting of an underlying systemic autoimmune disease, particularly systemic lupus erythematosus (SLE). SLE is a chronic autoimmune disease that can affect virtually any organ of the body due to the production of antinuclear antibodies. During the course of their disease, many patients develop pulmonary manifestations, including alveolar hemorrhage. We describe a clinical case of a 35-year-old woman with APS and SLE, anticoagulated with warfarin, who went to the emergency room with asthenia and productive cough with hemoptysis, and was diagnosed with a lupus flare and pulmonary-renal syndrome. Anticoagulation had to be discontinued due to the high risk of recurrent bleeding (HAS-BLED score 3). This case report describes the difficulty in managing the anticoagulant therapy in a patient with APS and SLE with both thrombotic and hemorrhagic manifestations.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

